New Alzheimer’s drug could be available next year, but are the risks worth the reward?
Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease.
These are very promising results, although the only data we have at the moment are from the drug manufacturer’s press release.
Lecanemab is an antibody that finds and removes amyloid.
By targeting amyloid, lecanemab is striking at the heart of the disease itself rather than just treating symptoms by boosting brain chemicals in the cells that are still working (as is the case with drugs currently prescribed for Alzheimer’s).
